Business
Aussie biotech Starpharma signs deal to sell COVID nose spray in Britain – Sydney Morning Herald
The Melbourne-based firm’s market value is approaching the billion-dollar mark amid rising investor interest in its COVID-preventative treatment.
Australian biotech Starpharma is taking its COVID-fighting antiviral nasal spray to the world, signing a deal with UK chemist chain LloydsPharmacy to sell the product in Britain as the country emerges from lockdown.
The Melbourne-based company announced a deal on Thursday morning that will see its Viraleze virus-fighting product sold online in the UK starting next week. It will also be stocked in Lloyds 1400-strong pharmacy network.
Chief executive Jackie Fairley declined to comment on the value…
-
Business21 hours agoWarning! These ASX 200 shares were just downgraded
-
Business14 hours agoMacquarie tips 14% upside for this ASX tech stock
-
Business14 hours agoThis ASX 200 media stock is storming 7% higher to 52-week highs. Here’s why.
-
Noosa News11 hours agoAFL live updates: Gold Coast vs Essendon – blog, scores and stats